• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Potential Consequences of Recurrent or Poorly Controlled MDD

Video

Consequences attributed to poorly controlled and recurrent MDD are evaluated by Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP.

Michael Rothrock, MBA, MHA: The potential consequences of recurrent or poorly controlled MDD [major depressive disorder] are going to drive potential additional health care resource utilization. That could be cognitive behavioral health, multiple physician visits, or hospitalization rates for those [whose disease is] uncontrolled. There could be development of resistance or lack of adherence because the patient isn’t seeing any benefit, doesn’t feel better, or [can’t] find a reason they need to take the drug. At the end of the day, these consequences are going to lead to poor control and limited improvement in outcomes.

H. Eric Cannon, PharmD, FAMCP: It has been a fascinating journey moving through the coronavirus disease 2019 pandemic. A number of people who were poorly treated to begin with suddenly had access issues getting into their physician. They felt like they were OK. However, in our emergency department, we’ve seen suicide rates and attempted suicides increase and a lot of people turn to self-medicating. The number of overdoses and things have increased at a pretty steep rate. Those consequences are severe, but we also overlook the consequences of what happens within a family. When you have a spouse who’s severely depressed, not getting treatment, or has stopped treatment, there are huge impacts in the basic social structure of their life.

Transcript edited for clarity.

Related Videos
Stephanie L. Graff, MD, an expert on breast cancer
B. Joy Snider, MD, PhD, and Maria Lopes, MD, MS
A panel of 5 experts on Alzheimer disease
Video 2 - "Payer Needs and Strategies for Evaluating and Covering PDTs"
Video 1 - "Differentiating PDTs from Wellness Apps and Evaluating Efficacy"
Chris Pagnani, MD, PC
Video 4 - "Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer"
Video 3 - "The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer"
Screenshot of Stephen Freedland, MD, during a video interview
"Integrating New PAH Therapies into Clinical Practice"
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.